Business
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence, and quality of life in chronic spinal cord injury VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spi
About this update from Nervgen Pharma Corp.
[{"type":"image","alt":"NervGen Pharma Corp.","displaySize":"","headline":null,"caption":"NervGen Pharma Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/0d20e81fbabc5cf778f980fa5d3f3b22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/on65M5UubYEttdyg2cfkEA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0d20e81fbabc5cf778f980fa5d3f3b22","width":300,"height":92}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence, and quality of life in chronic spinal cord injury","length":252,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":252,"olType":false},{"type":"text","content":"VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the Company will present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium, which is being held February 15-17, 2026, in Washington, DC.","length":497,"tagName":"p"},{"type":"text","content":"Details of the presentation are as follows:","length":43,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:10%;width:10%;min-width:10%;vertical-align:top;","val":[{"type":"text","content":"Title:","length":6,"tagName":"p","attribs":{}}]},{"style":"max-width:90%;width:90%;min-width:90%;","val":[{"type":"text","content":"Emerging Therapies with Challenges and Opportunities for the Future","length":67,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Format:","length":7,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Presentation and Panel Discussion","length":33,"tagName":"p"}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Date/Time:","length":10,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Sunday, February 15th, 2026, ...